Shots:
- Incyte has entered into a global collaboration & license agreement with Halozyme to evaluate additional SC formulations of INCA033989 for pts with mutCALR-expressing myeloproliferative neoplasms, using Halozyme’s Enhanze tech
- As per the deal, Halozyme will receive an upfront payment, as well as milestone payments, plus royalties, with Incyte having an option to nominate up to 2 additional targets for use with Enhanze
- Enhanze is a rHuPH20-based drug delivery technology that allows rapid SC administration of injected therapies & fluids to improve patient experience & reduce treatment burden
Ref: PRnewswire | Image: Incyte & Halozyme | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
